Neuroone Other Stockholder Equity from 2010 to 2024
| NMTC Stock | USD 0.76 0.02 2.70% |
Other Stockholder Equity | First Reported 2011-06-30 | Previous Quarter 74.6 M | Current Value 75.8 M | Quarterly Volatility 28 M |
Check Neuroone Medical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neuroone Medical's main balance sheet or income statement drivers, such as Interest Expense of 217.5 K, Selling General Administrative of 8.3 M or Total Revenue of 3.6 M, as well as many indicators such as Price To Sales Ratio of 27.3 K, Dividend Yield of 0.0 or Days Sales Outstanding of 20.4. Neuroone financial statements analysis is a perfect complement when working with Neuroone Medical Valuation or Volatility modules.
Neuroone | Other Stockholder Equity |
Latest Neuroone Medical's Other Stockholder Equity Growth Pattern
Below is the plot of the Other Stockholder Equity of Neuroone Medical Technologies over the last few years. It is Neuroone Medical's Other Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neuroone Medical's overall financial position and show how it may be relating to other accounts over time.
| Other Stockholder Equity | 10 Years Trend |
|
Other Stockholder Equity |
| Timeline |
Neuroone Other Stockholder Equity Regression Statistics
| Arithmetic Mean | 25,437,873 | |
| Geometric Mean | 881,638 | |
| Coefficient Of Variation | 125.88 | |
| Mean Deviation | 28,316,348 | |
| Median | 280,320 | |
| Standard Deviation | 32,020,966 | |
| Sample Variance | 1025.3T | |
| Range | 79.6M | |
| R-Value | 0.91 | |
| Mean Square Error | 193.3T | |
| R-Squared | 0.82 | |
| Slope | 6,503,308 | |
| Total Sum of Squares | 14354.8T |
Neuroone Other Stockholder Equity History
About Neuroone Medical Financial Statements
Neuroone Medical stakeholders use historical fundamental indicators, such as Neuroone Medical's Other Stockholder Equity, to determine how well the company is positioned to perform in the future. Although Neuroone Medical investors may analyze each financial statement separately, they are all interrelated. For example, changes in Neuroone Medical's assets and liabilities are reflected in the revenues and expenses on Neuroone Medical's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Neuroone Medical Technologies. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Other Stockholder Equity | 75.8 M | 79.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neuroone Medical Tec offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neuroone Medical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neuroone Medical Technologies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neuroone Medical Technologies Stock:Check out the analysis of Neuroone Medical Correlation against competitors. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuroone Medical. If investors know Neuroone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuroone Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.46) | Revenue Per Share 0.158 | Quarterly Revenue Growth 0.311 | Return On Assets (1.43) | Return On Equity (3.49) |
The market value of Neuroone Medical Tec is measured differently than its book value, which is the value of Neuroone that is recorded on the company's balance sheet. Investors also form their own opinion of Neuroone Medical's value that differs from its market value or its book value, called intrinsic value, which is Neuroone Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuroone Medical's market value can be influenced by many factors that don't directly affect Neuroone Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuroone Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuroone Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuroone Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.